Sitagliptin Therapy in Kidney Transplant Recipients With New-Onset Diabetes After Transplantation
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
New-onset diabetes after transplantation (NODAT) remains a frequent and serious complication after kidney transplantation (1). We previously reported NODAT in our postkidney transplant population at a frequency of more than 50%, using the definition established by the 2003 International Guidelines (2). This high rate of posttransplant diabetes has serious negative consequences for future cardiovascular risk and survival after kidney transplant (3). Many factors contribute to NODAT, including age, genetic background, obesity, and the use of immunosuppressants (2, 4). Despite the elimination of chronic glucocorticoids and minimization of immunosuppressants, NODAT remains a difficult problem (4). An ideal agent should stimulate beta-cell function, improve insulin resistance, be easily administered, and well tolerated without hypoglycemia. Finally, as our data have shown, NODAT occurs within the first 3 months posttransplant, so any pharmacologic intervention must be given soon after transplantation (2). The incretin class of agents may be suitable as treatment, or even prevention, for NODAT. These agents include glucagon-like peptide-1 agonists and the dipeptidyl peptidase (DPP)-4 inhibitors. They stimulate beta-cell function, slow gastric emptying, and decrease insulin resistance (5). The glucagon-like peptide-1 agonists also suppress appetite but may cause nausea and cannot be used with a low glomerular filtration rate (GFR). This leaves the orally administered DPP-4 inhibitors as potential candidates because they can be used with low GFR, infrequently cause nausea, and have a low hypoglycemia potential (6). We designed a 3-month pilot study to demonstrate the feasibility of using the DPP-4 inhibitor, sitagliptin, in a population of renal transplant recipients who had been diagnosed with NODAT. The primary endpoints included the effect of sitagliptin on tacrolimus and sirolimus levels and changes to renal function. Secondary endpoints included side effects and change in HbA1c. Fifteen patients were recruited for a 3-month study through the University of Nebraska Medical Center (UNMC) Clinical Research Center. The study was approved by the UNMC Institutional Review Board. All patients met the definition of NODAT (1). Patients had an estimated GFR (eGFR) more than 30 ml/min according to the Modification of Diet in Renal Disease study, were free of other chronic illnesses, and had a HbA1c of 6.5% to 10.0%. Our immunosuppression regimen was free of glucocorticoids and used low-dose tacrolimus (target levels 2–4 ng/mL) and sirolimus (target levels 4–6 ng/mL) (7). Patients were treated with sitagliptin at a standard dose of 100 mg orally each day with dosing adjusted based on eGFR, per package insert. Tacrolimus and sirolimus levels and serum creatinine were obtained weekly, while HbA1c was measured at 0 and 12 weeks. Patients were aged 52.1±4.0 years (mean±SD), 11 of 15 were male, 12 of 15 were whites, and body mass index was 34.0±1.8 kg/m2. They had been diagnosed with NODAT 1.8±0.3 years and were 4.7±1.0 years posttransplant. Mean blood pressure on entry was 139±5/78±3 mm Hg. Figure 1 demonstrates that over the course of the study, there was no significant change in tacrolimus or sirolimus levels, using nonparametric repeated measures analysis of variance testing. Similarly, there was no change in eGFR over the course of the study. eGFR was 58.9±4.4 mL/min at entry and 60.5±5.6 mL/min at week 12. Neither tacrolimus nor sirolimus doses changed over the study. HbA1c improved from a baseline of 7.2%±0.1% to 6.7%±0.2% (P=0.002).FIGURE 1.: Mean drug levels for sirolimus, tacrolimus, and eGFR over time. eGFR, estimated glomerular filtration rate.No patient discontinued the use of sitagliptin because of side effects. No patients had symptomatic hypoglycemia, although some were on more than one agent for NODAT. Side effects included mild abdominal discomfort, loose stools, nausea, and headaches. It should be noted that the highest rates of NODAT occur in patients who receive calcineurin inhibitors for immunosuppression (1). In addition, sirolimus has also been associated with NODAT (4). It is interesting to note that despite exposure to tacrolimus and sirolimus, there was an improvement in HbA1c similar to that seen in other patients with type 2 diabetes (8). These results suggest that further studies should be pursued with DPP-4 inhibitors in patients with NODAT, as part of a comprehensive treatment plan. This might even extend to treatment of patients without NODAT during the first 6 months after transplant, when immunosuppressant exposure is the greatest. In conclusion, we have shown that sitagliptin, in a pilot study, is capable of inducing a clinically significant decrease in HbA1c in patients who have NODAT after kidney transplant, without altering tacrolimus or sirolimus drug levels or eGFR and with minimal side effects. James T. Lane1 David E. Odegaard1 Claire E. Haire1 Dean S. Collier2 Lucile E. Wrenshall3 R.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Cited by
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s002 · Cited by 4,792
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s002 · Cited by 3,187
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s002 · Cited by 3,116
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Metadata
- Authors
- Lane, J. T., Odegaard, D. E., Haire, C. E., Collier, D. S., Wrenshall, L. E., & Stevens, R. B.
- Venue
- Transplantation
- Published
- 2011-11-27
- Volume
- 92
- Issue
- 10
- Pages
- e56-e57
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2024369575
- Cited by
- 79
- References
- 1
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sitagliptin Therapy in Kidney Transplant Recipients With New-Onset Diabetes After Transplantation. https://app.cochat.ai/papers/10.1097/tp.0b013e3182347ea4
- The paper
- Lane, J. T., Odegaard, D. E., Haire, C. E., Collier, D. S., Wrenshall, L. E., & Stevens, R. B. (2011). Sitagliptin Therapy in Kidney Transplant Recipients With New-Onset Diabetes After Transplantation. Transplantation. https://doi.org/10.1097/tp.0b013e3182347ea4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.